Analysis Shows No Benefit for Cytoreductive Nephrectomy Analysis Shows No Benefit for Cytoreductive Nephrectomy
For patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall survival, a new analysis concludes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Kluger appointed Cushing Professor of Internal Medicine and Dermatology
Harriet Kluger is an internationally renowned expert in the study and treatment of melanoma and renal cell carcinoma. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 18, 2022 Category: Universities & Medical Training Source Type: news
SPECT/CT proves value over CT diagnosing renal cancer
SPECT/CT imaging appears more accurate than standard contrast-enhanced CT exam...Read more on AuntMinnie.comRelated Reading:
Tc-99m SPECT/CT imaging detects COVID-19
SPECT/CT augmented reality may help visualize metastatic melanoma
SNMMI offers letter to contest SPECT/CT denials
Follow-up SPECT/CT scan tracks radionuclide dose
SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2022 Category: Radiology Source Type: news
Immunotherapy Combos Up Survival in Renal Cell Carcinoma Immunotherapy Combos Up Survival in Renal Cell Carcinoma
In the absence of head-to-head trials, the findings help validate the applicability of phase 3 results to routine care. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Renal Cell Carcinoma Highlights From ASCO-GU 2022 Renal Cell Carcinoma Highlights From ASCO-GU 2022
The role of immunotherapy at various disease stages and the predictive power of preoperative sarcopenia are among the highlights in renal cell carcinoma from ASCO-GU 2022 reviewed by Dr Brian Shuch.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Renal Cell Carcinoma: Achieving Complete Response Renal Cell Carcinoma: Achieving Complete Response
"One of the most gratifying patient experiences that I ' ve had," says Sandy Srinivas in recounting a patient with RCC who achieved a complete response.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Find Individuals That Inspire You Find Individuals That Inspire You
Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Unmet Needs in the Era of Precision Medicine for RCC Unmet Needs in the Era of Precision Medicine for RCC
Sandy Srinivas, MD, examines the current unmet needs for patients with renal cell carcinoma and discusses how the KEYNOTE-564 trial can help identify the right patient for the right therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer
The combination of stereotactic ablative body radiotherapy and a short-course of pembrolizumab is well tolerated and provides excellent local control of oligometastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 30, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs
NDA is supported by Allarity’s previously-filed pre-market approval (PMA) submission to the FDA for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 22, 2021 Category: Drugs & Pharmacology Source Type: news
Novel Agent May Be Game-Changer in Rare Genetic Disease Novel Agent May Be Game-Changer in Rare Genetic Disease
Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 1, 2021 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news
FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer
This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Keytruda Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions
Keytruda Is the First Immunotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
What Is the Most Common Type of Renal Cell Carcinoma?
Title: What Is the Most Common Type of Renal Cell Carcinoma?Category: Diseases and ConditionsCreated: 11/5/2021 12:00:00 AMLast Editorial Review: 11/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 5, 2021 Category: Cancer & Oncology Source Type: news
